UiPath Inc. (NYSE:PATH) Shares Sold by Bank Julius Baer & Co. Ltd Zurich

Bank Julius Baer & Co. Ltd Zurich lowered its stake in shares of UiPath Inc. (NYSE:PATH) by 62.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,537 shares of the healthcare company’s stock after selling 9,325 shares during the period. Bank Julius Baer & Co. Ltd Zurich’s holdings in UiPath were worth $138,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PATH. Royal London Asset Management Ltd. lifted its stake in shares of UiPath by 5.9% in the 3rd quarter. Royal London Asset Management Ltd. now owns 139,544 shares of the healthcare company’s stock valued at $2,388,000 after purchasing an additional 7,742 shares during the last quarter. O Shaughnessy Asset Management LLC acquired a new position in shares of UiPath in the 3rd quarter valued at $203,000. Invesco Ltd. lifted its stake in shares of UiPath by 2.8% in the 3rd quarter. Invesco Ltd. now owns 399,181 shares of the healthcare company’s stock valued at $6,830,000 after purchasing an additional 10,863 shares during the last quarter. Symmetry Partners LLC acquired a new position in shares of UiPath in the 4th quarter valued at $205,000. Finally, Toroso Investments LLC lifted its stake in shares of UiPath by 196.7% in the 3rd quarter. Toroso Investments LLC now owns 78,189 shares of the healthcare company’s stock valued at $1,338,000 after purchasing an additional 51,834 shares during the last quarter. Institutional investors and hedge funds own 62.50% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on PATH. BMO Capital Markets upped their price target on UiPath from $24.00 to $28.00 and gave the company a “market perform” rating in a research note on Thursday, March 14th. Wells Fargo & Company increased their target price on UiPath from $24.00 to $25.00 and gave the stock an “equal weight” rating in a research note on Thursday, March 14th. KeyCorp initiated coverage on UiPath in a research note on Monday, April 8th. They set an “overweight” rating and a $27.00 target price on the stock. Royal Bank of Canada reissued a “sector perform” rating and set a $29.00 target price on shares of UiPath in a research note on Monday, April 1st. Finally, Barclays increased their target price on UiPath from $23.00 to $25.00 and gave the stock an “equal weight” rating in a research note on Friday, March 15th. Nine research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $27.41.

UiPath Stock Performance

Shares of NYSE PATH opened at $19.46 on Monday. The stock’s 50-day moving average is $22.19 and its two-hundred day moving average is $21.61. UiPath Inc. has a 1-year low of $12.38 and a 1-year high of $27.87.

UiPath (NYSE:PATH) last released its quarterly earnings data on Wednesday, March 13th. The healthcare company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.10. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. The business had revenue of $405.25 million for the quarter, compared to the consensus estimate of $383.32 million. Sell-side analysts expect that UiPath Inc. will post -0.04 EPS for the current fiscal year.

Insider Activity

In other news, CFO Ashim Gupta sold 16,000 shares of the stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $22.84, for a total value of $365,440.00. Following the transaction, the chief financial officer now owns 87,505 shares in the company, valued at approximately $1,998,614.20. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last 90 days, insiders have sold 72,000 shares of company stock worth $1,591,360. 31.03% of the stock is currently owned by insiders.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.